Tioga Pharmaceuticals

CompanyUnited States

Tioga Pharmaceuticals develops one asset, in phase 2 (Asimadoline in vasomotor symptoms). Mostly small molecule acting on OPRK1; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
1
Signal

Pipeline

1
  • Asimadoline

    Activates peripheral kappa-opioid receptors to treat menopausal vasomotor symptoms.

    Phase 2, Small molecule, OPRK1, vasomotor symptoms

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1
  • Similar companies6

Intelligence